

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dominique BOUREL et al.
Title: USE OF ADCC-OPTIMIZED
ANTIBODIES FOR TREATING
WEAK PATIENTS
Appl. No.: 10/566,358
Filing Date: 04/13/2006
Examiner: Ilia I. OUSPENSKI
Art Unit: 1644
Confirmation 5572
Number:

SUPPLEMENTAL AMENDMENT AND REPLY UNDER 37 CFR 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This communication is responsive to the final Office Action of March 31, 2009, and the Advisory Action of July 1, 2009. This communication conforms the Amendment filed June 24, 2009, to the comments in section 3(d) of the Advisory Action (objectionable antibody recitations are now omitted). Thus, this Supplemental Amendment places the application in condition for allowance. Accordingly, Applicants request entry.

A concurrently filed one-month extension of time makes this filing timely.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks/Arguments begin on page 6 of this document.

Please amend the application as follows: